Vonoprazan Fumarate (TAK-438) , ≥98% , 1260141-27-2

CAS NO.：1260141-27-2

Empirical Formula: C21H20FN3O6S

Molecular Weight: 461.463

MDL number: MFCD18633280

EINECS: 250-635-4

PRODUCT Properties

• storage temp.: Store at -20°C
• solubility: insoluble in H2O; insoluble in EtOH; ≥18.9 mg/mL in DMSO
• form: solid
• InChIKey: ROGSHYHKHPCCJW-WLHGVMLRSA-N
• SMILES: N1(S(C2=CC=CN=C2)(=O)=O)C(C2=CC=CC=C2F)=CC(CNC)=C1.C(O)(=O)/C=C/C(O)=O

Description and Uses

Vonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.

Vonoprazan Fumarate is a novel potassium-?competitive acid blocker for the treatment of acid-?related diseases.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319-H335
• Precautionary statements: P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P321-P362+P364-P332+P313-P337+P313-P403+P233-P405-P501